65,437 trials
Healthy
Primary: Cmax - Maximum Observed Concentration — 5.2604; 5.4938 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 117.313; 116.452 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma — 1630.3; 1620.2 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration) - Glipizide in Plasma — 377.949; 381.282 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 32975.95; 33122.52 pg/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 27.080; 27.487 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 80.334; 71.483 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 57.26; 56.66 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 875.86; 886.39 ng/mL
Multiple Sclerosis, Relapsing-Remitting
Primary: Flu-like-syndrome — 17.4; 15.8; 31.1 Percentage of participants
Partial Edentulism
Primary: Osseous Integration — 145 participants
Mucopolysaccharidosis VI
Primary: Change From Baseline in 12-minute Walk Test at 24 Weeks — 109; 26 meters — p=0.025
Pulmonary Disease, Chronic Obstructive
Primary: Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years — -30; -30 ml/year — p=0.9524
Sepsis · Septic Shock
Primary: Cumulative Vasopressor Index (CVI) — 2.3; 3.0; -2.0; -1.4 units on a scale — p=0.238
Wrinkles in Frontal Area
Primary: Horizontal Action Halo Diameter at 28 Days — 1.0526; 1.0670 centimeter — p=0.832